Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health, Inc. (NYSE: CAH) is a global leader in integrated healthcare services and products. With nearly 100 years of experience, the company stands as a pillar in the healthcare industry, ranking among the top 25 on the Fortune 500 list. Cardinal Health offers a comprehensive suite of services that cater to hospital systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices worldwide.
Operating through two main segments—Pharmaceuticals and Medical—Cardinal Health provides clinically-proven medical products and pharmaceuticals, alongside cost-effective solutions that enhance supply chain efficiency. The company is a major distributor of branded, generic, and specialty pharmaceutical products to a wide array of clients, including retail chains, independent pharmacies, hospital networks, and healthcare providers.
Recently, Cardinal Health reported strong financial results for Q2 FY2024, with a 12% increase in revenue to $57.4 billion. The company also saw significant growth in both its Pharmaceutical and Medical segments, driven by robust sales of brand and specialty pharmaceuticals, as well as improvements in at-Home Solutions and Global Medical Products and Distribution. CEO Jason Hollar highlighted the company's operational execution and strategic priorities, which include tech-enabled specialty acquisitions and a focus on supply chain resiliency.
Cardinal Health is also committed to sustainability and corporate responsibility. The company recently released its Fiscal 2023 Environmental, Social and Governance (ESG) Report, emphasizing long-term value creation through sustainable practices. The company has received approval from the Science Based Targets initiative (SBTi) for its ambitious greenhouse gas (GHG) emissions reduction targets. By FY2023, Cardinal Health had already reduced its Scope 1 and 2 emissions by 13% from a FY2019 base year.
In terms of infrastructure, Cardinal Health is expanding its logistics capabilities. The company has commenced construction on a new 350,000 square-foot Consumer Health Logistics Center in Columbus, Ohio, designed to support the distribution of over-the-counter consumer health products. This facility, expected to be operational by Summer 2025, will create approximately 100 new jobs and enhance Cardinal Health's supply chain agility.
Despite challenges such as the non-renewal of its pharmaceutical distribution contracts with OptumRx, Cardinal Health remains resilient. The company reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance and is confident in its long-term growth targets.
For more information, visit cardinalhealth.com and follow @cardinalhealth on Twitter.
In a move to boost COVID-19 vaccination rates, four Ohio Managed Care Organizations (MCOs) have partnered with Outcomes, part of Cardinal Health (NYSE: CAH), to utilize local pharmacists for outreach to Medicaid members. The new Needs Immunization service aims to engage over 350,000 eligible participants through personalized consultations, addressing vaccine hesitancy. Pharmacists will connect with members to provide information and, if feasible, administer the vaccine. The initiative reflects the commitment of MCOs to enhance vaccination rates and combat hesitancy in underserved communities.
Cardinal Health (NYSE: CAH) announced the FDA's approval of LYMPHOSEEK® for pediatric use, enhancing lymphatic mapping and sentinel lymph node biopsies in children with solid tumors. This approval allows for improved disease staging in pediatric cancer patients, including those with melanoma and rhabdomyosarcoma. Clinical studies confirm LYMPHOSEEK® is safe for patients aged one month and older, with minimal adverse reactions. This development expands Cardinal Health's radiopharmaceutical offerings and strengthens its position in the precision healthcare market.
Cardinal Health's latest research reveals a growing comfort among oncologists with CAR-T cell therapy, with 60% finding costs reasonable, up from 39% in 2017. The report, based on surveys of 300+ U.S. oncologists, indicates a significant increase in referrals to CAR-T therapy, rising from 54% in 2019 to 91%. Despite these positive changes, challenges remain, including payer approvals and administrative hurdles. The research also highlights the ongoing impact of COVID-19 on cancer screening and the use of telemedicine in oncology.
Cardinal Health (NYSE: CAH) announced an irrevocable early redemption notice for its outstanding notes, totaling $500 million, due June 2022. The affected notes include $237.56 million at a rate of 3.200% and $262.44 million at 2.616%. The redemption date is set for June 15, 2021. The redemption prices will be determined based on specific terms outlined in the indentures, ensuring holders receive the greater of principal or present values of remaining payments. This move reflects Cardinal Health's strategy to manage debt effectively.
Cardinal Health (CAH) reported Q3 FY21 revenue of $39.3 billion, matching last year’s performance. However, GAAP operating earnings fell 16% to $473 million, influenced by a write-down related to the Cordis divestiture. Diluted EPS dropped to $0.40 due to a litigation tax effect. Non-GAAP operating earnings decreased 4% to $689 million, largely from COVID-19 impacts on the Pharmaceutical segment. The company narrowed its fiscal year 2021 EPS guidance to $5.90 to $6.05.
Cardinal Health (NYSE: CAH) has launched Outcomes, a digital ecosystem aimed at improving medication adherence by linking pharmacists, payers, and pharmaceutical companies. This initiative addresses the $528 billion annual cost of medication non-adherence in the U.S., which results in around 275,000 avoidable deaths each year. The Connect platform, part of Outcomes, integrates various existing Cardinal Health services and supports over 60,000 pharmacies and 23 million patients, enhancing clinical workflows and patient engagement.
On April 13, 2021, Cardinal Health (NYSE: CAH) announced it secured a $57.8 million contract with the U.S. Department of Health and Human Services for the storage and distribution of 80,000 pallets of personal protective equipment (PPE). This contract has the potential to reach $91.6 million if all options are exercised. Cardinal Health's extensive distribution network will enable rapid delivery of PPE to healthcare providers across the U.S. in response to ongoing public health emergencies, including the COVID-19 pandemic.
Cardinal Health (NYSE: CAH) has launched Cardinal Health™ Navista™ Tech Solutions (TS), designed to assist community oncologists in enhancing patient care and minimizing costs during the shift to value-based care. This suite includes integrated AI-enabled solutions such as Episode Analytics for cost tracking, CureMD Oncology Cloud for practice management, and CORE™ for population health support. By offering these tools, Cardinal Health aims to improve decision-making, automate processes, and reduce administrative burdens, ultimately driving better patient outcomes and financial performance.
Cardinal Health (NYSE: CAH) will release its financial results for Q3 fiscal year 2021 on May 6, before market opening. A webcast discussing these results will begin at 8:30 a.m. Eastern. The company specializes in distribution of pharmaceuticals and medical products, serving healthcare facilities globally, with operations in over 40 countries and approximately 48,000 employees. Interested parties can access the webcast and presentation on the Investor Relations page.
Cardinal Health (CAH) has signed an agreement to sell its Cordis business to Hellman & Friedman for approximately $1 billion. The divestiture, expected to close in the first half of fiscal year 2022, will decrease Cardinal Health's Medical segment profit by $60 million to $70 million annually. The company anticipates a pre-tax loss of up to $120 million for Q3 of fiscal year 2021 related to this transaction. Cardinal Health retains liability for certain lawsuits associated with Cordis post-sale.
FAQ
What is the current stock price of Cardinal Health (CAH)?
What is the market cap of Cardinal Health (CAH)?
What services does Cardinal Health offer?
How did Cardinal Health perform in Q2 FY2024?
What is Cardinal Health's approach to sustainability?
What are Cardinal Health's main business segments?
What recent infrastructure developments has Cardinal Health announced?
How many employees does Cardinal Health have?
What are Cardinal Health's fiscal 2024 guidance and expectations?
How is Cardinal Health addressing supply chain efficiency?
What impact will the non-renewal of OptumRx contracts have on Cardinal Health?
Where can I find more information about Cardinal Health?
